2026-04-14T03:19:21Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4274632026-03-13T04:35:50Zcom_2072_98col_2072_378192

00925njm 22002777a 4500 dc Vivanco-Hidalgo, Rosa Maria author Gómez González, Alejandra author Moreira Villanueva, Antía author Díez, Laura author Elosua, Roberto author Roquer González, Jaume author 2017 Altres ajuts: MSC/RD12-0042-0020 Altres ajuts: MSC/RD12/0042/0013 Epilepsy has been associated with cardiovascular comorbidity. This study aimed to assess the potential association between cardiovascular risk factors (s), antiepileptic drugs (s), and etiology. A single-center retrospective epilepsy cohort from the decade of 2004-2013 was assessed. Poisson regression models with robust variance were estimated to obtain prevalence ratios () according to prescription and etiology. After excluding patients in the monotherapy group with vascular etiology or previous cardiovascular events, in the remaining 400 patients, enzyme-inducer s (s), especially phenytoin (), were associated with higher prevalence of dyslipidemia (a 1.77, p < .05), compared to valproic acid. No etiology was associated with higher prevalence of any . Patients treated with s, especially , had higher prevalence of dyslipidemia. Antiepileptic drugs Cardiovascular risk factors Comorbidity Epilepsy Prevalence of cardiovascular risk factors in people with epilepsy